Close Menu

Courtagen

Investigators used gene panel sequence data to look at rare de novo variant frequencies in potential risk genes for neurodevelopmental disorders with epilepsy.

The number of US states legalizing cannabis for medical and recreational use is growing, expanding the market for pathogen detection solutions.

Going forward, the company will focus on its wholly owned subsidiary Medicinal Genomics Corporation, which conducts cannabis genetics research.

The SBIR Phase 1 award will go toward developing a test using immuno-PCR technology to detect toxins in medical marijuana. 

The two firms are collaborating on a system to share genotypic, phenotypic, and treatment outcomes data with physicians on a mobile-device network.

Courtagen will use its ZiPhyr bioinformatics pipeline to help Astellas develop a predictive model that can be used in early-stage drug development.

The life sciences company can now offer its genetic tests in all 50 states in the US, as well as Canada and several other countries. 

Courtagen Raises $20M

Proceeds from the financing will be used "to expand our ability to deliver leading-edge services to our customers," Courtagen's CEO said. 

A spokesman for Courtagen, which develops NGS-based tests for ailments such as mitochondrial disorders, the $7.5 million is part of a financing round expected to bring in about $17 million. 

The deals are with Pronto Diagnostics, headquartered in Tel Aviv, Israel and Medica Labs, based in Bangkok, Thailand.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.